Core Insights - The meeting held in Jiangsu aimed to facilitate communication between key hospitals and pharmaceutical companies to accelerate the implementation of innovative drugs and support high-quality development in the pharmaceutical sector [1] Group 1: Innovative Drug Development - Jiangsu's local pharmaceutical companies have consistently ranked first in the number of innovative drugs included in the national medical insurance directory, with 41 drugs expected to be approved by 2025, accounting for over one-third of the national total [1] - Among these, 21 are significant Class 1 innovative drugs, with 18 being original research drugs developed in Jiangsu, highlighting the province's core competitiveness in pharmaceutical innovation [1] Group 2: Economic Impact - The biopharmaceutical industry in Jiangsu has reached nearly 500 billion yuan in output value, maintaining its position as the leading province in the country [2] - The sales revenue of Zhengda Tianqing Pharmaceutical Group reached 22.5 billion yuan last year, contributing 2.18 billion yuan in taxes to Jiangsu [2] Group 3: Policy Support and Market Access - The Jiangsu government is actively creating platforms for communication to eliminate barriers for innovative drugs entering hospitals, which is crucial for enhancing clinical application [4] - By 2025, it is projected that 399 out of 406 national negotiated drugs will be sold and used in designated medical institutions in Jiangsu, with over 80% of the sales amount coming from these institutions [4] Group 4: Future Initiatives - Jiangsu plans to introduce an artificial intelligence application plan for the biopharmaceutical cluster this year, aiming to cultivate 1-2 industry models and gather typical AI-enabled solutions [7] - The province will also implement a budget policy that allows for separate budgeting for innovative drugs included in the national medical insurance directory, alleviating financial concerns for hospitals [7]

浦银国际研究 公司研究 | 医药行业 信达生物（1801.HK）：礼来战略合 作进一步提升公司国际化前景 信达是我们长期持续看好的生物科技龙头公司，重申"买入"评级， 上调目标价至 110 港元。 阳景 首席医药分析师 Jing_yang@spdbi.com (852) 2808 6434 胡泽宇 CFA 医药分析师 ryan_hu@spdbi.com (852) 2808 6446 2026 年 2 月 12 日 | 评级 | | | --- | --- | | 目标价（港元） | 110.0 | | 潜在升幅/降幅 | +23% | | 目前股价（港元） | 89.7 | | 52 周内股价区间（港元） | 34.6-109.1 | | 总市值（百万港元） | 155,559 | | 近 3 月日均成交额（百万） | 1,014 | 市场预期区间 SPDBI 目标价 ◆ 目前价 ◆市场预期区间 *数据截至 2026 年 2 月 11 日 资料来源：Bloomberg、浦银国际 HK$98.0 HK$89.7 HK$110.0 HK$137.4 股价表现 | 人民币百万元 | 2023 | 2024 | 2 ...

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) has shown a slight decline of 0.30% in its closing price, with a trading volume of 2.32 billion yuan on February 13, 2025. The fund has experienced growth in both its share count and total assets since the beginning of the year [1]. Fund Overview - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) was established on March 26, 2025, with an annual management fee of 0.40% and a custody fee of 0.07%. Its performance benchmark is the adjusted return of the National Index for Hong Kong Stock Connect Innovative Drugs [1]. - As of February 12, 2025, the fund's latest share count is 3.935 billion shares, with a total asset size of 5.214 billion yuan. Compared to December 31, 2025, the fund's shares have increased by 4.57% and its total assets by 9.73% [1]. Liquidity - Over the last 20 trading days, the cumulative trading amount for the Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) reached 7.823 billion yuan, with an average daily trading amount of 391 million yuan [1]. Fund Management - The current fund managers are Liu Weilin and Jiao Wendong. Liu has managed the fund since March 26, 2025, achieving a return of 31.76%, while Jiao has been managing it since April 10, 2025, with a return of 50.17% [2]. Top Holdings - The fund's top holdings include: - CSPC Pharmaceutical Group (石药集团) - 10.65% of the portfolio, valued at 506 million yuan - BeiGene (百济神州) - 10.10%, valued at 480 million yuan - CanSino Biologics (康方生物) - 9.91%, valued at 471 million yuan - China National Pharmaceutical Group (中国生物制药) - 9.85%, valued at 468 million yuan - Innovent Biologics (信达生物) - 9.72%, valued at 462 million yuan - 3SBio (三生制药) - 7.08%, valued at 337 million yuan - Hansoh Pharmaceutical (翰森制药) - 7.07%, valued at 336 million yuan - Kelun Pharmaceutical (科伦博泰生物-B) - 3.54%, valued at 168 million yuan - Kangzhe Pharmaceutical (康哲药业) - 2.60%, valued at 124 million yuan [3].

Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for Heng Rui Pharmaceutical (600276) and "Increase" for WuXi Biologics (603259) [46] Core Insights - The recent national drug procurement has been stable, with active participation from companies and continued benefits for patients [8][9] - The issuance of the "National Basic Drug Directory Management Measures" aims to enhance the management of essential medicines [10][11] - Heng Rui Pharmaceutical reported positive top-line results for its GLP-1/GIP dual receptor agonist, indicating significant weight loss in clinical trials [12] - The approval of Mu Feng Da® for the treatment of adult type 2 diabetes marks a significant development in the market [12] Industry News - The national drug procurement involved 316 commonly used drugs across 26 therapeutic areas, with a high participation rate from over 5,100 medical institutions and 1,091 companies [8][9] - The procurement process has been standardized, allowing companies to bid online once for nationwide sales, significantly reducing costs [9] - The management measures for the national basic drug directory have been revised to include legal policy bases and optimize the directory structure [10][11] Company Announcements - Innovent Biologics has entered a global strategic partnership with Eli Lilly to advance new drug development in oncology and immunology [26] - Kelun Pharmaceutical's TROP2 ADC has received approval for a fourth indication from the NMPA [27] - Heng Rui Pharmaceutical's drug has been included in the list of breakthrough therapy products, and its application for marketing approval has been accepted for priority review [28] - WuXi Biologics has forecasted a positive earnings outlook, expecting a revenue increase of approximately 16.7% [30] Market Review - The Shanghai Composite Index rose by 1.43%, while the Shenzhen Component Index increased by 2.37%, with the SW Pharmaceutical and Biotech Index up by 0.23% [36] - The industry’s price-to-earnings ratio (TTM) stands at 51.17, with a valuation premium of 259% compared to the CSI 300 [40] Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring performance recovery indicators [46]

中国银河证券研报认为，科技板块仍是中长期投资主线，经历近期的回调后，估值压力下降，相关板块 有望反弹回升，预计春节前后港股市场震荡上行。 港股通科技ETF海富通(513860)，紧密跟踪中证港股通科技指数，从港股通范围内选取50只市值较大、 研发投入较高且营收增速较好的科技龙头上市公司证券作为指数样本，截至最新，指数前五大中证一级 行业为：可选消费（37.02%）、信息技术（27.98%）、医药卫生（17.17%）、通信服务（16.31%）、 工业（1.52%）。场外联接(A类：021464；C类：021465) 风险提示：以上信息仅供参考，不构成投资建议。基金有风险，投资需谨慎。 截至2026年2月13日9:50，港股通科技ETF海富通(513860)小幅回调，成分股方面，九方智投控股涨超 5%，再鼎医药、联想集团、国药控股等涨超1%，信达生物、中芯国际、华虹半导体等跟涨。 资金净流入方面，Choice数据统计，截至2026年2月12日，港股通科技ETF海富通(513860)近3个月净流 入额增长 3.21亿元，近6个月净流入额增长18.26亿元，长期看增长显著。 从估值层面来看，港股通科技ETF海富通跟踪 ...

Group 1 - Morgan Stanley increased its stake in Innovent Biologics (01801) by 585,900 shares at a price of HKD 79.232 per share, totaling approximately HKD 46.422 million [1] - After the increase, the total number of shares held by Morgan Stanley is approximately 87,217,600, representing a stake of 5.02% [1]

农历新年前，中国创新药企业达成的几笔交易，给经历一轮上涨又陷入漫长蛰伏的板块带来暖意。 2026年以来，中国创新药对外授权交易总金额在短短四十多天里已超过300亿美元，首付款规模已超去 年全年单季度最高水平。数字之外，创新药BD（业务拓展）模式的调整，也映射出了中国企业在产业 链中能力与角色的变迁。 即便MNC当前对中国创新药资产的主动性需求更强，且白宫回应称并未"积极考虑"该草案，但BD作为 中国企业当前发展逻辑的关键一环，变幻莫测的地缘政治因素仍然会掣肘中国创新药行业。 图片来源：视觉中国 上周末，信达生物与礼来制药宣布达成新一轮全球战略合作，双方将共同推进肿瘤及免疫领域创新药物 的全球研发。根据协议，信达生物将获得3.5亿美元首付款。在达成后续特定里程碑事件后，信达生物 还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。 这是这家中国创新药公司与礼来的第七次合作。与以往不同的是，本次合作并未围绕公司已有的成熟分 子展开，而是针对尚未成型的新想法，MNC（跨国制药巨头）是为信达生物的早期研发平台和效率付 费，进行"端到端"的全球研发共建。 信达生物将运用其抗体技术平台，主导药物的早期研发，至 ...

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with limited disruptions, and institutions are increasing their positions in innovative companies, maintaining a positive outlook on undervalued innovative targets [1][4] - The overall market sentiment has improved, driven by significant business development transactions, and the pharmaceutical sector is expected to continue its steady growth in 2026, despite potential short-term volatility [4][5] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, ranking second among 12 industry indices [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - Since Q4 2025, the proportion of domestic capital holding pharmaceutical stocks through Hong Kong Stock Connect has slightly decreased, while foreign capital holdings have increased [32] - As of February 10, 2026, domestic holdings were at 22.2%, down 0.2 percentage points, while foreign holdings rose to 39.7%, up 0.9 percentage points [32] Sales Performance - In 2025, China's pharmaceutical market sales decreased by 1% year-on-year, with public hospitals accounting for the largest market share at 10,977 billion RMB, down 2.1% [5] - Retail pharmacy sales reached 5,878 billion RMB, growing by 2.4%, with online pharmacies seeing a significant increase of 13.6% [5] National Procurement - The recent national procurement round had a high selection rate of 93%, with 1,020 products from 1,091 participating companies expected to be implemented by the end of March 2026 [5] - The procurement process has seen increased participation and a diverse range of selected products, ensuring stability in clinical demand [5] Investment Recommendations - The report recommends focusing on innovative drugs, particularly companies like Sanofi and Hengrui Medicine, which have rich catalysts and clear long-term growth logic [4] - It also suggests looking into CXO companies benefiting from high downstream demand and improving financing conditions, such as WuXi AppTec [4]